Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis

Elaine Y L Cheong and Thomas Gottlieb
Med J Aust 2011; 194 (7): . || doi: 10.5694/j.1326-5377.2011.tb03018.x
Published online: 4 April 2011

To the Editor: Interest in alternative therapies for Clostridium difficile infections (CDIs) is increasing as these infections become important causes of patient morbidity and mortality. Recurrent CDIs can be severe and difficult to treat. In-vitro data,1 followed by reports of the efficacy of tigecycline in the treatment of severe refractory cases of CDI,2 suggest that tigecycline should be considered as an alternative or adjunctive antimicrobial agent in these situations. To date, it has been used mostly as a “salvage” strategy in combination with other antibiotics in the face of clinical deterioration.2,3 We report the successful use of tigecycline monotherapy in the treatment of a patient with recurrent C. difficile colitis.

  • Elaine Y L Cheong
  • Thomas Gottlieb

  • Concord Repatriation General Hospital, Sydney, NSW.

Competing interests:

Thomas Gottlieb is on the advisory boards of Pfizer, Janssen-Cilag and Novartis.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.